Tag Archive for: RNA

STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

/in

STORM’s first-in-class investigational drug STC-15 is the first clinical stage molecule specifically targeting an RNA methyltransferase STC-15 reshapes the tumour microenvironment and activates anti-tumour immunity 17 October 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, […]

Read more

STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference

/in

STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development. 9 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the […]

Read more

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

/in

Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development. 8 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and […]

Read more

STORM Therapeutics Presents STC-15 Preclinical Data Supporting Treatment of Patients with AML at the AACR Acute Myeloid Leukemia and Myelodysplastic Syndrome Conference

/in

Data demonstrates that STC-15, an oral METTL3 inhibitor, exhibits efficacy as a single agent and in combination with venetoclax using patient-derived tumor models STC-15 Phase 1 study in solid tumors aims to identify doses and regimen for potential clinical studies in AML and solid tumors 25 January 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical […]

Read more

The ‘must-attend’ Healthcare conferences of Q1 & Q2 2023

/in

… And just like that it’s ANOTHER new year! If you are still gathering your thoughts on how best to maximise your time in 2023, allow us to flag some of the most impactful and innovative conferences in Life Sciences. The Optimum team really enjoyed being back in person for the majority of the conferences […]

Read more